At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Fisetin +1 moredrug
Likely dose
Fisetin 20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients
In Brief
A Phase 2 clinical trial evaluating Fisetin and Placebo for Covid19 and Coronavirus Infection. Completed, enrolled 55 participants across 1 site.
Detailed Summary
The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Coronavirus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2021
Enrollment StartJul 2021
Primary CompletionSep 2022
TodayJul 2026
First PostedFeb 25, 2021
Enrollment StartJul 14, 2021
Primary CompletionSep 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.4 years ago
Interventions
Fisetindrug
\~20mg/kg /day oral for four days (days 0,1 and days 8,9)
Placebodrug
Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)